Peptide Database

Peptide NameErenumab

Function Ontology

Immunology ▸ Immune modulation ▸ Immunomodulatory activity

Standard StatusStandard

Sequence Length456 amino acids

Chemical FormulaC2240H3448N598O682S20

DescriptionStandard

        QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    

Molecular Weight50308.24 Da

Isoelectric Point (pI)8.44

Net Charge (pH 7.0)5.54

Net Charge (pH 7.4) 4.51

Charge Density (pH 7.0) 0.0121

GRAVY Index-0.36

Hydrophobic Moment 0.56

Boman Index0.01

Instability Index46.60

Aliphatic Index 66.97

Aromaticity 0.1031

Extinction Coeff. Reduced 73800.00

Extinction Coeff. Oxidized 74550.00

The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.

Amino Acid Composition

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.

2D CHEMICAL STRUCTURE

Drag to move

Drag to move. Use the buttons to zoom.

RECORD: Rec_0318142 VERIFIED: NO

Provenance & Taxonomy

OrganismHomo sapiens [Animal]; Cricetulus griseus [Animal]

FamilyMonoclonal antibody

Tax ID9606;10029

Structure & Mods

Configlinear peptide/protein therapeutic [Linear]

Chiralitycanonical L-amino-acid peptide [L]

Bio-Activity Profile

Function

Immunomodulatory

Half-LifeErenumab exhibits non-linear kinetics as a result of binding to the CGRP receptor [FDA Label]. Lower than 2-fold accumulation was recorded in trough serum concentrations (Cmin) for episodic and chronic migraine patients following subcutaneous administration of 70 mg once-monthly and 140 mg once-monthly doses [FDA Label]. Serum trough concentrations approached steady state by 3 months of dosing [FDA Label]. The effective half-life of erenumab was observed to be 28 days [FDA Label].